Status:
ACTIVE_NOT_RECRUITING
Ocular Rosacea Biome Study
Lead Sponsor:
University of California, San Francisco
Conditions:
Ocular Rosacea
Antimicrobial Resistance
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Ocular rosacea is an inflammatory disease of the eyelids and ocular surface. Like the facial disease, the ocular condition is chronic and recurrent. Sequelae of ocular rosacea vary from mild to severe...
Detailed Description
Even though SDD is widely used for the treatment of rosacea, very little confirmatory data exists, to indicate if this dose alters any other systemic mucosa flora or increases antibiotic resistance ra...
Eligibility Criteria
Inclusion
- Have symptomatic ocular disease attributed to ocular rosacea as the primary diagnosis
- Ability to give informed consent
- Be aged 18 years old or older
Exclusion
- Have an active ocular or systemic infection
- Have a known allergy or intolerance to tetracycline antibiotics
- Have had prior use of oral antibiotics within the last three months
- Pregnancy or the possibility of becoming pregnant within the 8-week study medication timeline.
Key Trial Info
Start Date :
June 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05296837
Start Date
June 22 2023
End Date
December 31 2026
Last Update
May 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Farncisco
San Francisco, California, United States, 94143